Active	Status	Sponsor type	Region	Phase	Filter
25 Active 4 Inactive 29 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

25 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Spriggs, Douglas
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN	Recruiting	N/A	1400	Europe, US, RoW	Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation	Medtronic Vascular	Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus	11/26	11/29
Koren, Michael J
NEWTON-CABG, NCT03900026: Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery	Recruiting	4	766	Canada, US	Evolocumab, Repatha®, Placebo, Control	Unity Health Toronto, Applied Health Research Centre	Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion	12/23	12/23
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
Cycle-2-PEF, NCT06215586: Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction	Recruiting	2	240	Europe, Canada, US, RoW	Tovinontrine (CRD-750, Placebo	Cardurion Pharmaceuticals, Inc.	Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases	10/25	10/25
Cycle-1-REF, NCT06215911: A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction	Recruiting	2	400	Europe, Canada, US, RoW	Tovinontrine (CRD-750), Placebo	Cardurion Pharmaceuticals, Inc.	Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases	10/25	10/25
DETECT-HF, NCT06378632: An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM	Recruiting	N/A	500	Europe, US, RoW	Hearo App	Cordio Medical	Heart Failure	07/25	07/25
NCT05646056: A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk	Completed	N/A	82	US	Software	Prolaio	Heart Failure, Cardiomyopathy, Hypertrophic, Left Ventricular Hypertrophy	09/24	09/24
Maney, Susan
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Stuart, Jill
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)	Recruiting	1/2	10	US	NRTX-1001, GABA-secreting interneurons	Neurona Therapeutics	Epilepsy, Temporal Lobe	07/26	07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	40	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis	05/25	05/26
Issa, Moises
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD	Recruiting	3	400	US	TQJ230, pelacarsen, Placebo	Novartis Pharmaceuticals	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	03/27	03/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease	Active, not recruiting	N/A	12000	Europe, US	Low-dose CT scan	Guardant Health, Inc.	Lung Cancer	12/25	12/25
NCT05860959: SUBLOCADE Long-term Outcomes	Recruiting	N/A	1200	Europe, Canada, US, RoW		Indivior Inc.	Opioid Use Disorder	08/27	08/27
Jenkins, Laura
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Petschonek, Leann
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
Marin, Aniel Navarro
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Guzman-Nguyen, Ayanna
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy	Recruiting	N/A	620	US	OPTIMIZER Smart System	Impulse Dynamics	Heart Failure	03/26	03/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Spriggs, Douglas
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN	Recruiting	N/A	1400	Europe, US, RoW	Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation	Medtronic Vascular	Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus	11/26	11/29
Koren, Michael J
NEWTON-CABG, NCT03900026: Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery	Recruiting	4	766	Canada, US	Evolocumab, Repatha®, Placebo, Control	Unity Health Toronto, Applied Health Research Centre	Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion	12/23	12/23
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
Cycle-2-PEF, NCT06215586: Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction	Recruiting	2	240	Europe, Canada, US, RoW	Tovinontrine (CRD-750, Placebo	Cardurion Pharmaceuticals, Inc.	Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases	10/25	10/25
Cycle-1-REF, NCT06215911: A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction	Recruiting	2	400	Europe, Canada, US, RoW	Tovinontrine (CRD-750), Placebo	Cardurion Pharmaceuticals, Inc.	Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases	10/25	10/25
DETECT-HF, NCT06378632: An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM	Recruiting	N/A	500	Europe, US, RoW	Hearo App	Cordio Medical	Heart Failure	07/25	07/25
NCT05646056: A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk	Completed	N/A	82	US	Software	Prolaio	Heart Failure, Cardiomyopathy, Hypertrophic, Left Ventricular Hypertrophy	09/24	09/24
Maney, Susan
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Stuart, Jill
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)	Recruiting	1/2	10	US	NRTX-1001, GABA-secreting interneurons	Neurona Therapeutics	Epilepsy, Temporal Lobe	07/26	07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	40	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis	05/25	05/26
Issa, Moises
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD	Recruiting	3	400	US	TQJ230, pelacarsen, Placebo	Novartis Pharmaceuticals	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	03/27	03/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease	Active, not recruiting	N/A	12000	Europe, US	Low-dose CT scan	Guardant Health, Inc.	Lung Cancer	12/25	12/25
NCT05860959: SUBLOCADE Long-term Outcomes	Recruiting	N/A	1200	Europe, Canada, US, RoW		Indivior Inc.	Opioid Use Disorder	08/27	08/27
Jenkins, Laura
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Petschonek, Leann
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
Marin, Aniel Navarro
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
Guzman-Nguyen, Ayanna
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy	Recruiting	N/A	620	US	OPTIMIZER Smart System	Impulse Dynamics	Heart Failure	03/26	03/26